Alkem Laboratories Ltd News

Nifty50 to hit 29,300 by end-2026? Nomura lists top 20 stock picks

Nomura expects Indian markets to trade in the range of 20-22x one-year forward earnings, assuming risk premia remain low.

Stocks to Watch today, Nov 21: RIL, TCS, Hyundai Motor, Adani Ports, Nestle

Stocks to Watch Today, November 11, 2025: Nestle India, Adani Ports, 360 ONE WAM, Alkem Laboratories, JSW Energy, and Zaggle Prepaid are among the top stocks to remain in focus today

Alkem Labs Q2 profit rises 11% on strong India, international sales

India sales grew 14% Y-o-Y to ₹2,766 crore in the September quarter, while international sales rose 29.5% to ₹1,189 crore, contributing 31.7% to overall revenue

Nifty MidCap can hit 25,000; these 5 stocks can rally up to 22%, say charts

The Nifty MidCap index can surge near 25,000-mark; whereas, midcap stocks such as AIA Engineering, Alkem Labs, Muthoot Finance, ICICI Prudential Life and UPL can rally another 22%, suggest tech charts

Nomura keeps Nifty target at 26,140, backs Swiggy, Titan, Alkem as top bets

Nomura has maintained its Nifty target for March 2026 at 26,140, implying a modest upside of 4 per cent from current levels, based on a FY27F earnings per share (EPS) estimate of ₹1,245.

Stocks to Watch today, Sept 29: Tata Motors, Oil India, BEML, Shriram Fin

Stocks to Watch today, September 29, 2025: From Tata Motors, Oil India to Shriram Finance, here is a list of stocks that will be in focus

Stocks to Watch today, Sept 23: Adani Power, KEC Int, JBM Auto, Vedanta

Stocks to Watch today, September 23, 2025: JBM Auto, Vedanta, JK Lakshmi, Dr Reddy's Labs and other stocks will be in focus

Alkem launches pertuzumab biosimilar for breast cancer in India

Alkem Laboratories on Monday said it has launched a biosimilar product in India for the treatment of breast cancer. The company has introduced Pertuza injection 420mg/14mL, a pertuzumab biosimilar, for the treatment of HER2-positive breast cancer, the drug firm said in a statement. Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab, it added. "Oncology is a priority area for Alkem, and our efforts are focused on developing treatment options that combine scientific excellence with wider access. The launch of Pertuza reflects this commitment and further strengthens our oncology portfolio," Alkem CEO Vikas Gupta said. Shares of the company on Monday ended 0.69 per cent down at Rs 5,496 apiece on BSE.

Alkem Labs Q1 profit rises 22% to ₹664 cr on India, overseas sales growth

Alkem Labs Q1FY26 profit rose 22% YoY to ₹664.3 crore, with strong growth in India and international sales; company to boost focus on high-potential non-US markets